CN112569323A - 一种解酒护肝的组合物及其应用 - Google Patents
一种解酒护肝的组合物及其应用 Download PDFInfo
- Publication number
- CN112569323A CN112569323A CN202011627414.9A CN202011627414A CN112569323A CN 112569323 A CN112569323 A CN 112569323A CN 202011627414 A CN202011627414 A CN 202011627414A CN 112569323 A CN112569323 A CN 112569323A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- lactobacillus
- composition
- percent
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 230000000694 effects Effects 0.000 title claims abstract description 47
- 210000004185 liver Anatomy 0.000 title claims abstract description 38
- 230000002633 protecting effect Effects 0.000 title claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 74
- 239000006041 probiotic Substances 0.000 claims abstract description 38
- 235000018291 probiotics Nutrition 0.000 claims abstract description 38
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 38
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 34
- 230000036541 health Effects 0.000 claims abstract description 20
- 229960003080 taurine Drugs 0.000 claims abstract description 19
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 18
- 201000007930 alcohol dependence Diseases 0.000 claims abstract description 18
- 239000011718 vitamin C Substances 0.000 claims abstract description 18
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 14
- 239000011720 vitamin B Substances 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000011691 vitamin B1 Substances 0.000 claims description 17
- 239000011716 vitamin B2 Substances 0.000 claims description 17
- 239000011726 vitamin B6 Substances 0.000 claims description 17
- 241000208340 Araliaceae Species 0.000 claims description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 16
- 235000008434 ginseng Nutrition 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 15
- 244000010000 Hovenia dulcis Species 0.000 claims description 13
- 235000008584 Hovenia dulcis Nutrition 0.000 claims description 13
- 244000046146 Pueraria lobata Species 0.000 claims description 13
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 13
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 12
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 12
- 235000017803 cinnamon Nutrition 0.000 claims description 12
- 244000062241 Kaempferia galanga Species 0.000 claims description 11
- 235000013421 Kaempferia galanga Nutrition 0.000 claims description 11
- 235000009421 Myristica fragrans Nutrition 0.000 claims description 11
- 239000001702 nutmeg Substances 0.000 claims description 11
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 10
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 10
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 10
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 10
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 10
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 10
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 10
- 240000000171 Crataegus monogyna Species 0.000 claims description 10
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 10
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 10
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 9
- 241000186012 Bifidobacterium breve Species 0.000 claims description 8
- 241001608472 Bifidobacterium longum Species 0.000 claims description 8
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000000529 probiotic effect Effects 0.000 claims description 8
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 7
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 5
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 5
- 244000199866 Lactobacillus casei Species 0.000 claims description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 5
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 5
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 5
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 5
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 5
- 244000270834 Myristica fragrans Species 0.000 claims description 5
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 5
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 5
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 5
- 229940017800 lactobacillus casei Drugs 0.000 claims description 5
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 3
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 3
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 3
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 3
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 3
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 3
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 3
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 3
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 3
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 3
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 241000194032 Enterococcus faecalis Species 0.000 claims description 2
- 241000628997 Flos Species 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 13
- 230000006870 function Effects 0.000 abstract description 12
- 239000003623 enhancer Substances 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 230000035764 nutrition Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 48
- 239000000047 product Substances 0.000 description 31
- 238000002156 mixing Methods 0.000 description 18
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 18
- 238000000605 extraction Methods 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 210000005229 liver cell Anatomy 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 9
- 229930003451 Vitamin B1 Natural products 0.000 description 9
- 229930003471 Vitamin B2 Natural products 0.000 description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 9
- 229960002477 riboflavin Drugs 0.000 description 9
- 229960003495 thiamine Drugs 0.000 description 9
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 9
- 235000010374 vitamin B1 Nutrition 0.000 description 9
- 235000019164 vitamin B2 Nutrition 0.000 description 9
- 235000019158 vitamin B6 Nutrition 0.000 description 9
- 229940011671 vitamin b6 Drugs 0.000 description 9
- 241000193749 Bacillus coagulans Species 0.000 description 8
- 229940054340 bacillus coagulans Drugs 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 241000498779 Myristica Species 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 235000008216 herbs Nutrition 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 5
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 229940126680 traditional chinese medicines Drugs 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 206010019133 Hangover Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 240000005250 Chrysanthemum indicum Species 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000021436 nutraceutical agent Nutrition 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
- -1 superoxide anions Chemical class 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000013252 liver disease animal model Methods 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000021485 packed food Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 108010023506 peroxygenase Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000028597 toxin metabolic process Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种解酒护肝的组合物及其应用，涉及保健品技术领域。本发明所述组合物包括药食同源的中药的水提物、益生菌、牛磺酸、维生素B和维生素C。本发明利用卫生部规定的药食两用生药原料，以及符合国家食品原料国标的营养强化剂原料制备所述组合物，兼具治疗和保健作用，可将其制备成具有相应功能的可长期食用的保健品，既有即时解酒又有长期服用保肝护肝的作用。
Description
技术领域
本发明属于保健品技术领域，具体涉及一种解酒护肝的组合物及其应用。
背景技术
世界卫生组织(WHO)指出，酒精中毒仍然是当今世界范围内的公害之一。饮酒过度现象以及由酒精所引发的疾病和问题也日益增多，且进入体内的乙醇大部分经肝脏代谢，对肝脏具有较强的毒性，例如使肝细胞膜表面的脂质过氧化以及破坏肝细胞膜，长期饮酒还会使肝细胞内的微管和线粒体等结构受到破坏，使细胞内的代谢紊乱，产生具有细胞毒性的代谢产物，导致肝细胞肿胀、坏死等等。
针对过量饮酒或酒精中毒等目前已有相关的化学药和中药，但是化学药本身也需要经肝脏代谢，代谢过程对肝脏同样具有毒性，故西药化学药只能在即时解决酒醉的不良反应，决不能作为长期调理的护肝保肝药物。同样的关于解酒的中药，大都是根据中药药味文献记载或古方文献记载，以及根据现代药理，提出的中药复方，虽能暂时缓解头晕、恶心等症状，但很多都含有使人兴奋的活性成分，只能治标不能治本。
虽然也有同时对脾气运化功能，肝气疏泄功能和肾气封藏功能的所谓标本兼治的中医理论，但鲜有现代药理实验证明，而且这类复方中药，都含有非药食两用的中药药味，即属治疗型，而不能长期服用调理。
发明内容
有鉴于此，本发明的目的在于提供一种解酒护肝的组合物及其应用，所述组合物既有解酒效果，又能长期服用，可制备成具有护肝保肝效果的食用保健品。
为了实现上述发明目的，本发明提供以下技术方案：
本发明提供了一种解酒护肝的组合物，所述组合物包括以下质量百分含量的组分：药食同源的中药的水提物66.3％～95.4％、益生菌2.5％～5.5％、牛磺酸0.15％～3.5％、维生素B 0.07％～0.75％和维生素C1％～4％。
优选的，所述组合物包括以下质量百分含量的组分：药食同源的中药的水提物72.7％～92.5％、益生菌3％～4％、牛磺酸2％～3％、维生素B 0.3％～0.45％和维生素C2％～3％。
优选的，所述药食同源的中药包括枳椇子、葛根、山楂、肉豆蔻、人参、菊花、高良姜和肉桂；且所述枳椇子、葛根、山楂、肉豆蔻、人参、菊花、高良姜和肉桂的质量比为(35～55)：(18～30)：(6～12)：(3～12)：(2～8)：(2～7)：(1.5～7)：(0.6～4)。
优选的，所述枳椇子、葛根、山楂、肉豆蔻、人参、菊花、高良姜和肉桂的质量比为(40～47)：(19～25)：(8～10)：(8～11)：(3～6)：(4～6)：(4～6)：(1～2)。
优选的，所述益生菌中包括植物乳杆菌、嗜酸乳杆菌、干酪乳杆菌、副干酪乳杆菌、鼠李糖乳杆菌、发酵乳杆菌、唾液乳杆菌、瑞士乳杆菌、罗伊氏乳杆菌、格氏乳杆菌、卷曲乳杆菌、约氏乳杆菌、保加利亚乳杆菌、嗜热链球菌、乳双歧杆菌、长双歧杆菌、短双歧杆菌、婴儿双歧杆菌、芽孢杆粪链球菌、两歧双歧杆菌和青春双歧杆菌中的两种或两种以上的混合。
优选的，所述维生素B包括维生素B1、维生素B2和维生素B6；且所述维生素B1、维生素B2和维生素B6的质量比为(0.023～0.25)：(0.023～0.25)：(0.023～0.25)。
优选的，所述维生素B1、维生素B2和维生素B6的质量比为(0.10～0.15)：(0.10～0.15)：(0.10～0.15)。
本发明还提供了上述组合物在制备具有解酒护肝效果的保健品中的应用。
本发明还提供了一种具有解酒护肝效果的保健品，所述保健品的有效成分包括上述组合物。
优选的，所述保健品的剂型包括颗粒剂、片剂或胶囊剂。
本发明提供了一种解酒护肝的组合物，包括药食同源的中药的水提物、益生菌、牛磺酸、维生素B和维生素C。本发明所述组合物的原料属于卫生部规定的药食两用生药原料，兼具治疗和保健作用；且生药原料以外的其他原料，都为符合国家食品原料国标的营养强化剂原料，其添加量都在法规允许范围内，可将其制备成具有相应功能的可长期食用的保健品，既有即时解酒又有长期服用保肝护肝的作用。
本发明所述组合物和保健品通过多个途径参与乙醇的代谢过程，降低乙醇对机体的伤害(包括降低乙醇、氧自由基和乙醛对机体的伤害)、调节乙醇代谢过程相关键酶活性尤其是提高乙醇脱氢酶活性加速乙醇代谢、提高乙醛脱氢酶活性、降低乙醛对机体伤害，同时还可以增加抗氧化活性成分，减少因乙醇代谢过程产生的自由基对机体的伤害。
具体实施方式
本发明提供了一种解酒护肝的组合物，所述组合物包括以下质量百分含量的组分：药食同源的中药的水提物66.3％～95.4％、益生菌2.5％～5.5％、牛磺酸0.15％～3.5％、维生素B 0.07％～0.75％和维生素C1％～4％。
本发明所述组合物中药食同源的中药(也称生药)的水提物质量百分含量优选为72.7％～92.5％。本发明所述药食同源的中药优选包括枳椇子、葛根、山楂、肉豆蔻、人参、菊花、高良姜和肉桂；且所述枳椇子、葛根、山楂、肉豆蔻、人参、菊花、高良姜和肉桂的质量比优选为(35～55)：(18～30)：(6～12)：(3～12)：(2～8)：(2～7)：(1.5～7)：(0.6～4)，更优选为(40～47)：(19～25)：(8～10)：(8～11)：(3～6)：(4～6)：(4～6)：(1～2)。
本发明对所述水提物(也称生药提取物)的制备方法并没有特殊限定，既可以将所述中药分别提取后混合，也可以混合后再共同提取，还可以任意两种或多种中药混合后提取；当分别提取时，各生药的提取方法相同，以枳椇子为例，进行说明，包括以下步骤：将生药枳椇子置于提取灌中，用8～12倍质量的饮用水进行微沸第一提取，并过60～100目筛；滤渣再经6～10倍质量的饮用水进行1～2次微沸提取，过60～100目筛；弃去滤渣，合并滤液，静置过夜，取上清液真空浓缩，至含固量约20％(或比重1.02～1.1(热测))的浸膏；喷雾干燥，制得生药的提取物；将利用上述方案制备得到的各生药的提取物混合后即可作为总生药提取物。当共同提取时，将所述生药按照上述比例混合后，依据上述方案进行相同的提取即可。
在本发明中，枳椇子“止呕逆”、“止咳除烦，去膈上热。润五脏，利大小便”，与李东垣的《脾胃论》对酒伤治疗所述“汗出则愈矣，其次莫如利小便”相符；葛根“解肌发表出汗”，同时“能治天行上气，呕逆，开胃下食，主解酒毒，止烦渴”，水提物中所含的葛根异黄酮等生物活性物质，能提高肝脏乙醇脱氢酶和乙醛脱氢酶的活性；过氧酶类等活性成分具有醒酒安神作用。葛根和枳椇子具有协同解酒作用。
在本发明中，山楂水提物中总黄酮含量可高达85％，可降低高脂饲料所致SD大鼠肝组织丙二醛(MDA)、总胆固醇(TC)等的含量，清除肝内堆积的三酰甘油，减少脂肪酸(FFA)对肝细胞毒性作用，能降低丙氨酸氨基转移酶(ALT)、天门冬酸氨基转移酶(AST)等肝功能指标，达到调节血脂、保肝作用；同时还具很强的抗氧化活性，对羟自由基和超氧阴离子有清除和抑制作用，且作用强度与浓度正相关；且能提高体内超氧化物歧化酶(SOD)活性。此外山楂水提物中还含多种有机酸，口服能增加胃中消化酶的分泌，增强脂肪酶、蛋白酶的活性。山楂还能促进肠道蠕动，对肠道功能紊乱有明显的双向调节作用。这些有对解酒护肝都具有很强的相关性作用。
在本发明中，肉豆蔻“消宿食，解酒毒”。动物试验证明，其能显著提高抗氧化酶系统中超氧化物歧化酶(SOD)活性，阻止自由基的脂质过氧化作用。显著降低脂质过氧化产物丙二醛(MDA)含量，从而显著降低对肝脏的损伤；能显著减少并降低因D-氨基半乳糖(GaIN)模型小鼠肝损伤模型造成的肝细胞变性、坏死。
在本发明中，人参能促进动物模型提高还原型谷胱甘肽(GSH)的含量和乙醇脱氢酶(ADH)含量，并显著降低乙醇模型小鼠血中乙醇浓度；同时人参可以促进葛根中的异黄酮类成分溶出，并增加人参皂苷的含量。葛根和人参混合提取比分别提取更有益于ADH活性增加，且两者混合提取液更有益于其他的体内酶活性的增加。
在本发明中，菊花主要活性成分为黄酮类化合物和绿原酸。具有疏风、清热、明目、解毒的功效，主要治疗头痛，眩晕，目赤，心胸烦热，疗疮，肿毒等症。《本草纲目》中称野菊花有“利五脉、调四肢，治头风热、脑骨肿痛、养目血、去翳膜，主肝气不足”。《药鉴》载其“解醉汉昏迷，易醒，共干葛(也叫葛花)煎汤”。同时，菊花具有较强的抗氧化作用，可提高小鼠谷胱甘肽过氧化物活性，清除氧自由基，具有保肝功能。
在本发明中，高良姜味辛热，有散寒止痛、温中止呕之功，“暖胃散寒，消食醒酒，治胃院冷痛”。在本发明所述组合物中，具有温中止呕，消化、健胃、止呕作用。药理学研究表明，其具有抗溃疡、抗腹泻、镇痛抗炎、抗血栓形成、抗氧化、抗菌等药理活性，姜能显著降低急性酒精性肝损伤小鼠血清GPT水平。
在本发明中，肉桂味辛、甘，性大热，能散寒通经、引火归源，而关于其解药毒之殊用，历代本草亦见散在记载。肉桂能制约金石等热药毒，这与其引火归元的特性相关，能发汗疏通血脉，宣导百药。肉桂辛以善行，热则温通，能导诸药通行于血脉经络，但凡药毒害人，其毒内结于血脉之中，无外泄之机，毒难排解，蓄积伤人，肉桂起到芳香宣导透毒外出，加速毒素代谢的作用。肉桂之宣透与其他解表透邪药又有所不同，其性能走能守，既能通经宣透，亦能补火助阳、引火归元。且肉桂的水提物有超强的抗氧化活性，具有很强的抗自由基活性，可提高超氧化物歧化酶(SOD)活性，能降低自由基代谢产物(MDA)含量，能提高神经生长因子(nerve growth factor，NGF)、脑源性神经生长因子(brainnerve growthfactor，BDNF)表达，改善血液流变学，改善慢性脑缺血大鼠的认知能力。
本发明所述组合物中，所述益生菌的质量百分含量为2.5％～5.5％，优选为3％～4％，可满足每天人服用益生菌量≥360亿CFU/天·人即可。本发明所述益生菌中优选包括植物乳杆菌、嗜酸乳杆菌、干酪乳杆菌、副干酪乳杆菌、鼠李糖乳杆菌、发酵乳杆菌、唾液乳杆菌、瑞士乳杆菌、罗伊氏乳杆菌、格氏乳杆菌、卷曲乳杆菌、约氏乳杆菌、保加利亚乳杆菌、嗜热链球菌、乳双歧杆菌、长双歧杆菌、短双歧杆菌、婴儿双歧杆菌、凝结芽孢杆菌、两歧双歧杆菌和青春双歧杆菌中的两种或两种以上的混合。在本发明中，所述益生菌为一类活菌制剂，具有平衡肠道菌群、抑制潜在致病菌、增加肠黏膜抵抗力的作用，可在多个水平下调内源性炎症介质，同时利用益生菌还能改善肠道菌群结构，有利于慢性肝病动物模型恢复转氨酶水平、减少脂肪沉积、减轻肝脏炎症反应。本发明对上述益生菌的各菌种及来源并没有特殊限定，利用本领域的常规市售菌种即可。
本发明所述组合物中，维生素B的质量百分含量为0.07％～0.75％，优选为0.30～0.45％。本发明所述维生素B优选包括维生素B1、维生素B2和维生素B6；且所述维生素B1、维生素B2和维生素B6的质量比优选为(0.023～0.25)：(0.023～0.25)：(0.023～0.25)，更优选为(0.10～0.15)：(0.10～0.15)：(0.10～0.15)。在本发明中，B族维生素可作为机体反应酶的合成原料，可改善脂肪蛋白质的代谢，助消化，并参与体内各种蛋白酶的作用和体内多种新陈代谢反应。充足的B族维生素，能避免肝脂肪变性，提高肝脏对乙醇的耐受力，消除乙醇和烟焦油等内毒素，保护肝脏，从而具有防止脂肪肝的功效和养肝功效。
本发明所述组合物中，牛磺酸的质量百分含量为0.15％～3.5％，优选为2％～3％。在本发明中，所述牛磺酸是细胞内含量最丰富的含磺酸基的β自由氨基酸，可以维持组织渗透压、稳定细胞膜、抗氧化应激、调节免疫力、维持细胞钙离子水平、保护线粒体、抑制肝细胞活性氧产生以及明显提高肝脏中乙醇脱氢酶和乙醛脱氢酶的活性，减少过氧化物酶的释放，可有效保护肝细胞。同时牛磺酸还可以抑制脂质过氧化，减少MDA并保护胰岛β细胞功能等广泛生物学效应；还具有加速乙醇的代谢、抗炎等多种生理功能。此外牛磺酸通过加速或对肝细胞极低密度脂蛋白分泌的保护作用，可防止高脂血清诱发的原代培养肝细胞脂肪变。牛磺酸还能减少造模大鼠肠道对高脂饮食中TG和TC的吸收，促进肝脏脂质代谢，从而防止高脂血症和肝脂肪变性的发生，能有效的保护肝脏因乙醇引起的伤害。
本发明所述组合物中，维生素C的质量百分含量为1％～4％，优选为2％～3％。在本发明中，所述维生素C是一种强还原剂，可以保护其他抗氧化剂，防止自由基对人体的伤害，保护细胞、解毒、保护肝脏。它还能促进许多体内抗氧化酶的氧化型转为还原型，从持续发挥抗氧化作用。
本发明所述组合物中优选还包括余量的辅料，所述辅料的质量优选为所述组合物质量的0～20％。本发明对所述辅料的种类和用量并没有特殊限定，优选根据不同的剂型进行常规选择即可。由此，本发明所述组合物通过多个途径参与乙醇的代谢过程，降低乙醇对机体的伤害，既有即时解酒又有长期服用保肝护肝作用。
本发明还提供了上述组合物在制备具有解酒护肝效果的保健品中的应用。
本发明还提供了一种具有解酒护肝效果的保健品，所述保健品的有效成分包括上述组合物。本发明所述保健品的剂型优选包括颗粒剂、片剂或胶囊剂。本发明所述保健品优选的每天服用5g，即每天服用益生菌活菌量为360～750亿/人·天。
下面结合实施例对本发明提供的一种解酒护肝的组合物及其应用进行详细的说明，但是不能把它们理解为对本发明保护范围的限定。
实施例1
1、按表1所示配制生药；
表1生药组成
| 生药名称 | 生药比例％ |
| 枳椇子 | 47 |
| 葛根 | 25 |
| 山楂 | 8 |
| 肉豆蔻 | 8 |
| 人参 | 3 |
| 菊花 | 4 |
| 高良姜 | 4 |
| 肉桂 | 1 |
| 合计 | 100 |
2、生药原料提取(混合提取)
将表1所述生药混合一起置于提取灌中，加总生药重量10倍量饮用水，加热至沸，保持微沸2h，80目过滤，收集滤液；滤渣继续加水8倍，加热至沸，保持微沸1.5h，80目过滤，滤渣弃去，滤液与上述滤液合并，静置过夜，取上清液真空浓缩，至含固量约20％(或比重1.02～1.1左右(热测)的浸膏)，将此浸膏喷雾干燥，控制进风温度为150～190℃，出风80～95℃，得浸膏粉；将此粉过100目筛，制得配方原料生药的混合提取物，即为总生药提取物。
3、产品制备(固体饮料，配方如表2)
表2固体饮料配方
| 名称 | 原辅料比例％ |
| 总生药提取物 | 72.7 |
| 益生菌(规格：3×10<sup>11</sup>cfu/g) | 3 |
| 牛磺酸 | 2 |
| 维生素B1 | 0.1 |
| 维生素B2 | 0.1 |
| 维生素B6 | 0.1 |
| 维生素C | 2 |
| 赤藓糖醇、三氯蔗糖 | 20 |
| 合计 | 100 |
1)配方称量
按表2所述配方称取总生药提取物、益生菌(植物乳杆菌0.6％、嗜酸乳杆菌0.6％、鼠李糖乳杆菌0.6％、格氏乳杆菌0.6％、嗜热链球菌0.6％)、牛磺酸、维生素B1、维生素B2、维生素B6、维生素C和赤藓糖醇(19.5％)、三氯蔗糖(0.5％)，为备用1。
2)混合制粒干燥
取已称取的备用1中的总生药提取物、牛磺酸、赤藓糖醇，置混合机混合均匀后，混合粉体置流化床，用水作粘合剂，进行制粒，至含水量3～5％，出料。经10目筛网摇摆式颗粒机整粒，得制粒颗粒。
3)总混：
取已称取的备用1中的益生菌、维生素B1、维生素B2、维生素B6、维生素C、三氯蔗糖先人工混合均匀，再与上述已制得的颗粒置混合机混合均匀，为备用2。
4)固体饮料灌装：
选择适当铝箔包装材料。调节灌装机至2.5克/支。取备用2灌装密封。装量误差符合相应包装食品要求。
5)产品活性检测
5.1)氧化自由基吸收能力(ORAC)分析检测结果，该产品ORAC值为3500(μmol TE/g)。
5.2)益生菌活菌含量检测：9×109(cfu/g)，约225亿/支。
建议服用量：解酒：饮酒前后各服一次，每次1～2支，通常保健：每天2支。活菌每天服用量为450亿。
实施例2
1、按表3所示比例配置生药
表3生药配制比例
| 生药名称 | 生药比例％ |
| 枳椇子 | 40 |
| 葛根 | 19 |
| 山楂 | 10 |
| 肉豆蔻 | 11 |
| 人参 | 6 |
| 菊花 | 6 |
| 高良姜 | 6 |
| 肉桂 | 2 |
| 合计 | 100 |
2、生药原料提取(混合提取)
除生药配制比例不同外，其余操作与实施例1相同。
3、产品制备(胶囊剂)
表4产品配方
1)配方称量
按表4所示配方称取总生药提取物、益生菌(鼠李糖乳杆菌0.8％、乳双歧杆菌0.8％、长双歧杆菌0.8％、短双歧杆菌0.8％、凝结芽孢杆菌0.8％)、牛磺酸、维生素B1、维生素B2、维生素B6、维生素C和硬脂酸镁，为备用1。
2)混合制粒干燥
取已称取的备用1中的总生药提取物、牛磺酸、置混合机混合均匀后，混合粉体置流化床，用水作粘合剂，进行制粒，至含水量3～5％，出料。经10目筛网摇摆式颗粒机整粒，得制粒颗粒。
3)总混：
取已称取的备用1中的益生菌、维生素B1、维生素B2、维生素B6、维生素C、硬脂酸镁，先人工混合均匀，再与上述已制得的颗粒置混合机混合均匀，为备用2。
4)灌装：
选择0#号硬胶囊囊壳。调节灌装至0.5g/粒。灌装胶囊。装量误差符合相应保健食品要求。
5)产品活性检测
5.1)氧化自由基吸收能力(ORAC)分析检测结果，该产品ORAC值为4300(μmol TE/g)。
5.2)益生菌活菌含量检测：9×109(cfu/g)，约45亿/粒。
建议服用量：解酒：饮酒前后各服一次，每次4～5粒，通常保健：每天2次，每次3～4粒。活菌每天服用量约为360～480亿/天·人。
实施例3
1、按表5所示比例配制生药
表5生药配制比例
| 生药名称 | 生药比例％ |
| 枳椇子 | 45 |
| 葛根 | 22 |
| 山楂 | 8 |
| 肉豆蔻 | 9 |
| 人参 | 5 |
| 菊花 | 5 |
| 高良姜 | 4.5 |
| 肉桂 | 1.5 |
| 合计 | 100 |
2、生药原料提取(各生药分别提取)
按表5所示配方分别称取生药枳椇子、葛根、山楂、高良姜、肉豆蔻、菊花、肉桂、人参。分别置提取灌中，分别加该种生药重量10倍量饮用水，加热至沸，保持微沸1.5h，80目过滤，收集滤液；滤渣继续加水8倍，加热至沸，保持微沸1h，80目过滤，滤渣弃去，滤液与上述滤液合并，静置过夜，取上清液真空浓缩，至含固量约20％(或比重1.02～1.1左右(热测)的浸膏)；将此浸膏喷雾干燥，控制进风温度为150～190℃，出风80～95℃，得浸膏粉；将此粉过100目筛，制得各味生药的提取物，将制得的各生药提取物混合后作为总生药提取物。
3、产品制备(片剂)：
表6产品配方
1)配方称量
按表6所示配方称取总生药提取物、益生菌(干酪乳杆菌0.8％、副干酪乳杆菌0.8％、发酵乳杆菌0.8％、两歧双歧杆菌0.8％、凝结芽孢杆菌0.8％)、牛磺酸、维生素B1、维生素B2、维生素B6、维生素C和微晶纤维素(10％)、硬脂酸镁(0.55％)，为备用1。
2)混合制粒干燥
取已称取的备用1中的总生药提取物、牛磺酸、及微晶纤维素，置混合机混合均匀后，混合粉体置流化床，用水作粘合剂，进行制粒，至含水量3～5％，出料。经10目筛网摇摆式颗粒机整粒，得制粒颗粒。
3)总混：
取已称取的备用1中的益生菌、维生素B1、维生素B2、维生素B6、维生素C和硬脂酸镁，先人工混合均匀，再与上述已制得的颗粒置混合机混合均匀，为备用2。
4)压片：
选用合适片型及片重的冲头，调节片重至0.75g/片，进行压片，片剂要求硬度为大于5kg，崩解时间在60min以内。压片后，再进行薄膜包衣，包衣粉用量为素片重量的3％。
5)产品活性检测
5.1)氧化自由基吸收能力(ORAC)分析检测结果，该产品ORAC值为3900(μmol TE/g)。
5.2)益生菌活菌含量检测：1.2×1010(cfu/g)，约90亿/片。
建议服用量：解酒：饮酒前后各服一次，每次3～4片。通常保健：每天2次，每次2～3片。活菌每天服用量约为360～540亿/天·人。
实施例4
除益生菌组成与实施例3不同外，其余均相同，本实施例中的益生菌(4％，规格3×1011cfu/g)组成为：青春双歧杆菌1％、长双歧杆菌1％、短双歧杆菌1％、凝结芽孢杆菌1％。
实施例5
除益生菌组成与实施例3不同外，其余均相同，本实施例中的益生菌(4％，规格3×1011cfu/g)组成为：植物乳杆菌0.4％、嗜酸乳杆菌0.4％、鼠李糖乳杆菌0.4％、格氏乳杆菌0.4％、嗜热链球菌0.4％、干酪乳杆菌0.4％、副干酪乳杆菌0.4％、发酵乳杆菌0.4％、两歧双歧杆菌0.4％和凝结芽孢杆菌0.4％。
实施例6
除益生菌组成与实施例3不同外，其余均相同，本实施例中的益生菌(4％，规格3×1011cfu/g)组成为：鼠李糖乳杆菌0.40％、乳双歧杆菌0.40％、长双歧杆菌0.40％、短双歧杆菌0.40％、凝结芽孢杆菌0.40％、青春双歧杆菌0.40％、长双歧杆菌0.40％、短双歧杆菌0.40％、两歧双歧杆菌0.40％和凝结芽孢杆菌0.40％。
实施例7
除总生药提取物占比、益生菌组成及占比与实施例3不同外，其余均相同，本实施例中的总生药提取物(80％)，益生菌(3％，规格3×1011cfu/g)组成为：长双歧杆菌1％、短双歧杆菌1％、凝结芽孢杆菌1％。
对实施例2和实施例3制备得到的保健品进行动物试验：
构建小鼠醉酒模型：适应性饲养后，小鼠随机分成7组(正常组、醉酒组、醉酒+海王金樽、醉酒+受试物组，每组10个动物。
分组信息如下：正常对照组(n＝10)，不做处理；模型对照组(n＝10)，等体积赋形剂；阳性对照1(n＝10)，海王金樽(1.5g/kg)；受试样品(1.5和3g/kg，n＝10)。
试验当日，各组小鼠给予赋形剂、海王金樽或受试物灌胃(体积25ml/kg)，半小时后，各组小鼠给予乙醇(浓度50％)20ml/kg体重，记录醉酒潜伏期(灌酒后至翻正反射消失)、醉酒时间(反射消失至反射恢复)。
苏醒后：
摘眼球取血，分离血清，测定肝功能指标(ALT(IU/L)、AST(IU/L)、TBIL(μmol/L)、ALP(IU/L))；
实验样品小鼠服用量为人体的20倍，其中解酒试验指标包括：反射消失时长和反射恢复时间；对肝脏影响的指标包括：谷丙转氨酶、谷草转氨酶、总胆红素、碱性磷酸酶。并以市售的海王金樽作为阳性对照。其中实施例2和实施例3两个样品的各项指标(表7～12)都优于阳性对照海王金樽，且与模型组比较，经统计分析，都具显著性，P值*＜0.05和极显著性，P值**＜0.01。
表7保健品对反射消失时长的影响(用量均为3g/kg)
| 反射消失时长(min) | 模型 | 海王金樽 | 实施例2* | 实施例3** |
| mean均值 | 18.4 | 13.6 | 35 | 28 |
| SD方差 | 5.680375574 | 4.788875999 | 19.24693338 | 4.666666667 |
| 显著性P值 | 0.025000651 | 0.002173431 |
表8保健品对反射恢复时长的影响(用量均为3g/kg)
| 反射恢复时间(min) | 模型 | 海王金樽 | 实施例2* | 实施例3* |
| mean均值 | 744.5 | 708 | 616.1111111 | 623.7777778 |
| SD方差 | 69.72732606 | 108.012345 | 88.17375523 | 69.77961339 |
| 存活率％ | 60 | 70 | 90 | 90 |
| 显著性P值 | 0.239323573 | 0.026232911 | 0.017284511 |
表9保健品对谷丙转氨酶的影响(用量均为1.5g/kg)
表10保健品对谷草转氨酶的影响(用量均为1.5g/kg)
表11保健品对总胆红素的影响(用量均为1.5g/kg)
表12保健品对碱性磷酸酶的影响(用量均为1.5g/kg)
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种解酒护肝的组合物，其特征在于，所述组合物包括以下质量百分含量的组分：药食同源的中药的水提物66.3％～95.4％、益生菌2.5％～5.5％、牛磺酸0.15％～3.5％、维生素B 0.07％～0.75％和维生素C1％～4％。
2.根据权利要求1所述组合物，其特征在于，所述组合物包括以下质量百分含量的组分：药食同源的中药的水提物72.7％～92.5％、益生菌3％～4％、牛磺酸2％～3％、维生素B0.3％～0.45％和维生素C 2％～3％。
3.根据权利要求1或2所述组合物，其特征在于，所述药食同源的中药包括枳椇子、葛根、山楂、肉豆蔻、人参、菊花、高良姜和肉桂；且所述枳椇子、葛根、山楂、肉豆蔻、人参、菊花、高良姜和肉桂的质量比为(35～55)：(18～30)：(6～12)：(3～12)：(2～8)：(2～7)：(1.5～7)：(0.6～4)。
4.根据权利要求3所述组合物，其特征在于，所述枳椇子、葛根、山楂、肉豆蔻、人参、菊花、高良姜和肉桂的质量比为(40～47)：(19～25)：(8～10)：(8～11)：(3～6)：(4～6)：(4～6)：(1～2)。
5.根据权利要求1所述组合物，其特征在于，所述益生菌中包括植物乳杆菌、嗜酸乳杆菌、干酪乳杆菌、副干酪乳杆菌、鼠李糖乳杆菌、发酵乳杆菌、唾液乳杆菌、瑞士乳杆菌、罗伊氏乳杆菌、格氏乳杆菌、卷曲乳杆菌、约氏乳杆菌、保加利亚乳杆菌、嗜热链球菌、乳双歧杆菌、长双歧杆菌、短双歧杆菌、婴儿双歧杆菌、芽孢杆粪链球菌、两歧双歧杆菌和青春双歧杆菌中的两种或两种以上的混合。
6.根据权利要求1所述组合物，其特征在于，所述维生素B包括维生素B1、维生素B2和维生素B6；且所述维生素B1、维生素B2和维生素B6的质量比为(0.023～0.25)：(0.023～0.25)：(0.023～0.25)。
7.根据权利要求6所述组合物，其特征在于，所述维生素B1、维生素B2和维生素B6的质量比为(0.10～0.15)：(0.10～0.15)：(0.10～0.15)。
8.权利要求1～7任一项所述组合物在制备具有解酒护肝效果的保健品中的应用。
9.一种具有解酒护肝效果的保健品，其特征在于，所述保健品的有效成分包括权利要求1～7任一项所述组合物。
10.根据权利要求9所述保健品，其特征在于，所述保健品的剂型包括颗粒剂、片剂或胶囊剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011627414.9A CN112569323A (zh) | 2020-12-31 | 2020-12-31 | 一种解酒护肝的组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011627414.9A CN112569323A (zh) | 2020-12-31 | 2020-12-31 | 一种解酒护肝的组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112569323A true CN112569323A (zh) | 2021-03-30 |
Family
ID=75144917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011627414.9A Pending CN112569323A (zh) | 2020-12-31 | 2020-12-31 | 一种解酒护肝的组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112569323A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113273659A (zh) * | 2021-06-03 | 2021-08-20 | 佛山市朗芯生物科技有限公司 | 一种含益生菌的解酒护肝功能性固体饮料及其制备方法 |
| CN113768153A (zh) * | 2021-09-14 | 2021-12-10 | 浙江省农业科学院 | 一种解酒组合物、制备方法及其应用 |
| CN115006460A (zh) * | 2022-06-22 | 2022-09-06 | 山东禾宝药业有限公司 | 一种解酒护肝中药组合物及其制备方法和应用 |
| CN115336699A (zh) * | 2022-09-14 | 2022-11-15 | 上海菌小宝健康科技有限公司 | 一种有助于肝脏健康的复合益生菌粉剂及其制备方法 |
| CN115944087A (zh) * | 2023-01-16 | 2023-04-11 | 深圳市君恒生物科技有限公司 | 一种解酒护肝的益生菌组合物、产品及其应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101775347A (zh) * | 2010-02-05 | 2010-07-14 | 中山大学 | 一种保健醋及其醋饮料的制备方法与解酒护肝应用 |
| CN103285252A (zh) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | 一种解酒护肝口服液及其制备方法 |
| CN105285260A (zh) * | 2015-11-30 | 2016-02-03 | 李嘉 | 一种解酒保健茶 |
| CN105902922A (zh) * | 2016-04-18 | 2016-08-31 | 合肥九研医药科技开发有限公司 | 一种具有解酒护肝功能的组合物及其制备方法 |
| CN107050148A (zh) * | 2017-06-13 | 2017-08-18 | 广州中天康顺生物医药有限公司 | 一种解酒保肝中药组合物及其制备方法 |
| CN107568736A (zh) * | 2017-07-04 | 2018-01-12 | 劲膳美食品股份有限公司 | 解酒醒酒医学配方食品 |
| CN111249347A (zh) * | 2018-11-30 | 2020-06-09 | 内蒙古伊利实业集团股份有限公司 | 解酒护肝组合物及产品 |
-
2020
- 2020-12-31 CN CN202011627414.9A patent/CN112569323A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101775347A (zh) * | 2010-02-05 | 2010-07-14 | 中山大学 | 一种保健醋及其醋饮料的制备方法与解酒护肝应用 |
| CN103285252A (zh) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | 一种解酒护肝口服液及其制备方法 |
| CN105285260A (zh) * | 2015-11-30 | 2016-02-03 | 李嘉 | 一种解酒保健茶 |
| CN105902922A (zh) * | 2016-04-18 | 2016-08-31 | 合肥九研医药科技开发有限公司 | 一种具有解酒护肝功能的组合物及其制备方法 |
| CN107050148A (zh) * | 2017-06-13 | 2017-08-18 | 广州中天康顺生物医药有限公司 | 一种解酒保肝中药组合物及其制备方法 |
| CN107568736A (zh) * | 2017-07-04 | 2018-01-12 | 劲膳美食品股份有限公司 | 解酒醒酒医学配方食品 |
| CN111249347A (zh) * | 2018-11-30 | 2020-06-09 | 内蒙古伊利实业集团股份有限公司 | 解酒护肝组合物及产品 |
Non-Patent Citations (1)
| Title |
|---|
| 黄世敬等: "《古今解酒醒酒妙验方》", 28 February 2013, 金盾出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113273659A (zh) * | 2021-06-03 | 2021-08-20 | 佛山市朗芯生物科技有限公司 | 一种含益生菌的解酒护肝功能性固体饮料及其制备方法 |
| CN113768153A (zh) * | 2021-09-14 | 2021-12-10 | 浙江省农业科学院 | 一种解酒组合物、制备方法及其应用 |
| CN115006460A (zh) * | 2022-06-22 | 2022-09-06 | 山东禾宝药业有限公司 | 一种解酒护肝中药组合物及其制备方法和应用 |
| CN115336699A (zh) * | 2022-09-14 | 2022-11-15 | 上海菌小宝健康科技有限公司 | 一种有助于肝脏健康的复合益生菌粉剂及其制备方法 |
| CN115944087A (zh) * | 2023-01-16 | 2023-04-11 | 深圳市君恒生物科技有限公司 | 一种解酒护肝的益生菌组合物、产品及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112569323A (zh) | 一种解酒护肝的组合物及其应用 | |
| JP5340302B2 (ja) | キグシを含む加味雙和湯を有効成分として含有する二日酔い解消用組成物 | |
| EP3530277A1 (en) | Chinese medicine healthcare preparations for slimming and weight loss | |
| TWI500391B (zh) | 解酒與預防宿醉的組合物及包含組合物的飲料 | |
| CN107568736A (zh) | 解酒醒酒医学配方食品 | |
| KR101930483B1 (ko) | 발효 청미래덩굴 잎 및 이의 추출물 | |
| CN105942498A (zh) | 具有治疗糖尿病作用的功能性营养食品组合及其制备方法 | |
| KR101977908B1 (ko) | 아토피성 피부염 개선제 및 이의 제조방법 | |
| KR101687982B1 (ko) | 정자수 증가와 환경호르몬 예방효과를 갖는 성기능 개선용 조성물 및 그의 제조방법 | |
| CN108882730B (zh) | 一种调节人体肠胃机能的饮品 | |
| CN108936628A (zh) | 一种脑卒中患者食用的特定全营养配方食品及其制备方法 | |
| CN108968037A (zh) | 老年痴呆症全营养配方食品 | |
| CN104187613A (zh) | 失眠全营养配方食品 | |
| CN110604800A (zh) | 一种戒酒解酒护肝植物饮品及制备方法 | |
| CN105708970B (zh) | 一种具有降血糖功能的保健食品 | |
| KR101826737B1 (ko) | 생약재 추출물을 유효성분으로 하는 근육틱 및 우울증 개선용 조성물 및 그의 제조방법 | |
| KR100988923B1 (ko) | 쌍화탕 유산균 발효물을 포함하는 숙취해소용 조성물 | |
| KR20090056383A (ko) | 쌍화탕 유산균 발효물을 유효성분으로 함유하는 간 독성예방 또는 치료용 조성물 | |
| CN108936607A (zh) | 慢性阻塞性肺疾病全营养配方食品 | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| CN110973625A (zh) | 基于火麻仁的护肝醒酒组合物及其制备方法和应用 | |
| CN111135235A (zh) | 一种预防和缓解急性酒精中毒或醉酒的组合物 | |
| CN111298020B (zh) | 具有抗疲劳功效的中药组合物及其制备方法与应用 | |
| CN110050972B (zh) | 芦荟山楂球及其制备方法 | |
| CN115089661A (zh) | 辅助调节内分泌代谢并抗癌防癌的人参组合物的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |